OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107) : reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinibWHITE, Deborah L; SAUNDERS, Verity A; DANG, Phuong et al.Blood. 2006, Vol 108, Num 2, pp 697-704, issn 0006-4971, 8 p.Article

A high-performance liquid chromatography―mass spectrometry assay for quantitation of the tyrosine kinase inhibitor nilotinib in human plasma and serumPARISE, Robert A; EGORIN, Merrill J; CHRISTNER, Susan M et al.Journal of chromatography. B. 2009, Vol 877, Num 20-21, pp 1894-1900, issn 1570-0232, 7 p.Article

Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL⁺ leukemiasWEISBERG, Ellen; CATLEY, Laurie; HALL-MEYERS, Elizabeth et al.Blood. 2007, Vol 109, Num 5, pp 2112-2120, issn 0006-4971, 9 p.Article

Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107)VON BUBNOFF, Nikolas; MANLEY, Paul W; MESTAN, Jurgen et al.Blood. 2006, Vol 108, Num 4, pp 1328-1333, issn 0006-4971, 6 p.Article

Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cellsFISKUS, Warren; PRANPAT, Michael; ATADJA, Peter et al.Blood. 2006, Vol 108, Num 2, pp 645-652, issn 0006-4971, 8 p.Article